BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, January 24, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

July 26, 2024

View Archived Issues
Diseased liver

As target organ, liver can influence which metastases take

Not all cancer cells that detach from the primary tumor and embark on a journey to another organ colonize it. To establish themselves, cells need specific conditions. Scientists at the Federal Institute of Technology Zurich (ETH Zurich) explored this hypothesis in the liver and identified a protein involved in metastatic transformation. Blocking it prevented liver metastasis. Their findings may have applications in other organs and various types of cancers. Read More

SP-1-303 inhibits ER-positive breast cancer cell proliferation

Researchers from Shuttle Pharmaceuticals LLC and Georgetown University have described the in vitro and in vivo profile of SP-1-303, designed as a dual-function histone deacetylase (HDAC) inhibitor and ataxia-telangiectasia mutated protein (ATM) activator, in breast cancer models. Read More
Illustration of herpes simplex virus particles

Long-acting helicase-primase inhibitor prevents HSV recurrences

Half of the individuals with genital herpes simplex virus (HSV) infection experience several recurrence episodes per year, especially if the causative agent is HSV type 2 (HSV-2). Standard-of-care viral DNA polymerase inhibitors are not fully effective in preventing recurrences and managing symptoms. Read More
Child feet

Medannex awarded funding to study therapy in pediatric osteosarcoma

Medannex Ltd. has been awarded an Innovate UK grant to fund a £313,000 (US$403,000) project developing a new treatment for pediatric osteosarcoma. Innovate UK will fund £231,000 (US$297,000) of the project costs, with the remainder financed by Medannex. Read More

MET degradation inducers described in Oncozen patent

Oncozen Co. Ltd. has patented new proteolysis targeting chimera (PROTAC) compounds comprising a heat shock protein 90 (HSP90) binding moiety covalently bound to hepatocyte growth factor receptor (HGFR; MET) targeting moiety through a linker. Read More
Woman receiving chemotherapy

Z-526 reverts chemotherapy-induced cachexia in preclinical models

Chemotherapy usually induces cachectic muscle loss through different mechanisms. Among these, oxidative stress is known to decrease protein synthesis and increase proteolysis leading to muscle atrophy. Read More

‘We're always on the lookout for what's next’

From no hope to viable treatments, BioWorld  is there to cover the breakthroughs in medicine. Listen to Randy Osborne explain why the BioWorld  team is ‘always on the lookout for what's next.’ Read More
Illustration of hookworms in foot

Novel heterocycle substituted aminamidine derivative shows potent, rapid anthelmintic activity against N. americanus

Researchers from the Chinese Center for Disease Control and Prevention detailed the discovery of novel aromatic heterocycle substituted aminamidine derivatives (AADs) for the treatment of Necator americanus infection (hookworms). Read More

Insilico Medicine discloses new PTPN2 inhibitors

Insilico Medicine Inc. has identified compounds acting as tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) inhibitors reported to be useful for the treatment of cancer and metabolic disease. Read More

Hainan Simcere Pharmaceutical patents new FGFR3 inhibitors

Hainan Simcere Pharmaceutical Co. Ltd. has prepared bicyclic compounds acting as fibroblast growth factor receptor 3 (FGFR3) inhibitors potentially useful for the treatment of cancer. Read More
Sickle-cell-pic.png

Actinium Pharmaceuticals obtains FDA clearance for trial of Iomab-ACT in sickle cell disease

Actinium Pharmaceuticals Inc. has received FDA clearance of an IND application to study Iomab-ACT for targeted conditioning prior to a bone marrow transplant (BMT) in patients with sickle cell disease.  Read More

Apichope Pharmaceutical identifies new RIPK1 inhibitors

Patents from Apichope Pharmaceutical Co. Ltd. describe bicyclic compounds characterized as receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors. Read More

Genescience Pharmaceuticals patent reports new camptothecin derivatives

Camptothecin derivatives reported to be useful for the treatment of cancer have been disclosed in a recent Genescience Pharmaceuticals Co. Ltd. patent. Read More
Zebrafish

New adult zebrafish model for studying SDHB-associated phaeochromocytomas and paragangliomas

Phaeochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors arising from chromaffin cells chromaffin cells in the adrenal medulla or extra-adrenal paraganglia, respectively. Read More

Other news to note for July 26, 2024

Additional early-stage research and drug discovery news in brief, from: Enveric Biosciences, Inozyme Pharma, Mira Pharmaceuticals.  Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 23, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 23, 2026.
  • Illustration of human body surrounded by DNA, cell and drug icons

    Cell/gene therapy sector now sustainable; China competition mounting

    BioWorld
    There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
  • Illustration of magnifying glass inspecting brain

    Neurotrimin unveiled as marker in intellectual disability

    BioWorld Science
    Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
  • DNA mutations or genetic disorder concept art

    Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

    BioWorld Science

    Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing